Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysisElectronic supplementary information (ESI) available: IR, MAS and NMR spectra. See DOI: 10.1039/c7md00178a
P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P-gp could have potential cancer therapeutic applications by preventing or reversing MDR. To exploit this, we designed twenty-five...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Journal Article |
Language | English |
Published |
18.10.2017
|
Online Access | Get full text |
Cover
Loading…
Abstract | P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P-gp could have potential cancer therapeutic applications by preventing or reversing MDR. To exploit this, we designed twenty-five tetrahydroquinolinone analogs bearing pyridyl methyl carboxylate at C
3
and different substituents at C
4
as MDR reversal agents. The inhibitory effects of the synthesized compounds against P-gp were assessed by flow cytometric determination of rhodamine 123 accumulation in P-gp over-expressing MES-SA/DX5 cells. Fluorescence imaging of intracellular rhodamine 123 accumulation in MES-SA/DX5 cells was also performed. Furthermore, the effect of active derivatives on the reduction of doxorubicin's IC
50
in MES-SA/DX5 cells was evaluated using MTT assay. Molecular docking was used to confirm the binding mode of some of the synthesized compounds. Five compounds in group A, bearing a 2-pyridyl methyl ester substituent at the C
3
position, significantly increased rhodamine accumulation at 25 μM comparable to verapamil, a well-established P-gp inhibitor, while only 2 compounds in group B bearing 3-pyridyl methyl ester at the same position had this effect. This study shows that tetrahydroquinolinones containing methyl pyridine esters could represent an attractive scaffold for the discovery of P-gp inhibitors as MDR reversal agents in cancer cells.
Tetrahydroquinolinones bearing a phenyl ring with electron-withdrawing substitution showed remarkable P-glycoprotein inhibitory activity and significantly increased rhodamine accumulation in MES-SA/DX5 cells. |
---|---|
AbstractList | P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P-gp could have potential cancer therapeutic applications by preventing or reversing MDR. To exploit this, we designed twenty-five tetrahydroquinolinone analogs bearing pyridyl methyl carboxylate at C
3
and different substituents at C
4
as MDR reversal agents. The inhibitory effects of the synthesized compounds against P-gp were assessed by flow cytometric determination of rhodamine 123 accumulation in P-gp over-expressing MES-SA/DX5 cells. Fluorescence imaging of intracellular rhodamine 123 accumulation in MES-SA/DX5 cells was also performed. Furthermore, the effect of active derivatives on the reduction of doxorubicin's IC
50
in MES-SA/DX5 cells was evaluated using MTT assay. Molecular docking was used to confirm the binding mode of some of the synthesized compounds. Five compounds in group A, bearing a 2-pyridyl methyl ester substituent at the C
3
position, significantly increased rhodamine accumulation at 25 μM comparable to verapamil, a well-established P-gp inhibitor, while only 2 compounds in group B bearing 3-pyridyl methyl ester at the same position had this effect. This study shows that tetrahydroquinolinones containing methyl pyridine esters could represent an attractive scaffold for the discovery of P-gp inhibitors as MDR reversal agents in cancer cells.
Tetrahydroquinolinones bearing a phenyl ring with electron-withdrawing substitution showed remarkable P-glycoprotein inhibitory activity and significantly increased rhodamine accumulation in MES-SA/DX5 cells. |
Author | Firuzi, O Edraki, N Shahraki, O Ranjbar, S Khoshneviszadeh, M Miri, R Saso, L |
AuthorAffiliation | Zahedan University of Medical Sciences School of Pharmacy Department of Medicinal Chemistry Shiraz University of Medical Sciences Department of Physiology and Pharmacology "Vittorio Ersparmer" Medicinal and Natural Products Chemistry Research Center Sapienza University of Rome |
AuthorAffiliation_xml | – name: Department of Medicinal Chemistry – name: Shiraz University of Medical Sciences – name: Department of Physiology and Pharmacology "Vittorio Ersparmer" – name: School of Pharmacy – name: Medicinal and Natural Products Chemistry Research Center – name: Sapienza University of Rome – name: Zahedan University of Medical Sciences |
Author_xml | – sequence: 1 givenname: S surname: Ranjbar fullname: Ranjbar, S – sequence: 2 givenname: O surname: Firuzi fullname: Firuzi, O – sequence: 3 givenname: N surname: Edraki fullname: Edraki, N – sequence: 4 givenname: O surname: Shahraki fullname: Shahraki, O – sequence: 5 givenname: L surname: Saso fullname: Saso, L – sequence: 6 givenname: M surname: Khoshneviszadeh fullname: Khoshneviszadeh, M – sequence: 7 givenname: R surname: Miri fullname: Miri, R |
BookMark | eNqFkE1PAjEQhhujiYhcvJuMN00AuyyGj5tRjBxQA9zJ0C3LaLetbXeT_eceLWr0YKJzmc_3eZM5YvvaaMnYScK7CU9Hl2JQZJwngyHusUaP93mnd5Uk-981Tw9Zy_tnHiPtDYejfoO9LWVwuK0zZ15L0kbRDgqZdFRhoEp6QA_WBKkDPHVyVQtjXWxJA-ktrSkY58dR4CnXbfC1DttY-zasySiTk0AFskJVRpzRgDqDwigpSoUOMiNeSOdxiqqOqklcBGc0CfCltUoW0RddHb02xhWfiPPJYnoBWCEpXCs5hum8DbPrxQf7YTYHb3cU7MJCSrh9nI7h94uO2cEGlZetr9xkp3eT5c19x3mxso6K6Lr6OU-b7Oyv_cpmm_Q_xjs4bYp0 |
ContentType | Journal Article |
DOI | 10.1039/c7md00178a |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2040-2511 |
EndPage | 1933 |
ExternalDocumentID | c7md00178a |
GroupedDBID | -JG 0-7 705 7~J AAEMU ABGFH ACLDK ADSRN AEFDR AFVBQ AGSTE AUDPV BSQNT C6K EE0 EF- H~N J3I RCNCU RPMJG RRC RSCEA SKF SKH SKJ SKM SKR SKZ SLC SLF SMJ |
ID | FETCH-rsc_primary_c7md00178a3 |
ISSN | 2040-2503 |
IngestDate | Mon Jan 28 17:14:44 EST 2019 Sun Jun 02 15:21:47 EDT 2019 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-rsc_primary_c7md00178a3 |
Notes | Electronic supplementary information (ESI) available: IR, MAS and NMR spectra. See DOI 10.1039/c7md00178a |
PageCount | 15 |
ParticipantIDs | rsc_primary_c7md00178a |
ProviderPackageCode | J3I ACLDK RRC 7~J SKZ AEFDR SLC RCNCU SLF EE0 RSCEA AFVBQ C6K H~N 0-7 RPMJG -JG AGSTE AUDPV EF- BSQNT SKF SKH SMJ SKJ SKM ADSRN ABGFH SKR 705 AAEMU |
PublicationCentury | 2000 |
PublicationDate | 20171018 |
PublicationDateYYYYMMDD | 2017-10-18 |
PublicationDate_xml | – month: 10 year: 2017 text: 20171018 day: 18 |
PublicationDecade | 2010 |
PublicationYear | 2017 |
References_xml | – issn: 2005 publication-title: Principles of internal medicine doi: Hauser JAMERSON – issn: 2016 publication-title: World doi: Stewart Wild |
SSID | ssj0000328894 |
Score | 4.28114 |
Snippet | P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical... |
SourceID | rsc |
SourceType | Enrichment Source Publisher |
StartPage | 1919 |
Title | Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysisElectronic supplementary information (ESI) available: IR, MAS and NMR spectra. See DOI: 10.1039/c7md00178a |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3NT9swFMCtjl24TIOBBgz0DggNNWGl6UfaG4IiOqm0KkXiVjlxSoMgrZIUKfyt-0N25D27iVM1k7ZdospW0sTvp-dn-30wdsztitPwKq7pikbFpBnCbKEZb_JmzbPrE8e1Zfm23m3j5r7286H-UCr9ynktLWLnzH0rjCv5H6liG8qVomT_QbLZQ7EBf6N88YoSxuvfydiLUVckgrS7H1D5nVlAcVChLFlG-WR5VJ7PYjrvH5iPz4k7k3kZfHJvnPqOT6V2aE9ASD8OGu4oCdAkjFTmAZWhSYpRZwWXxw0vaVXdskCFqgIdVXaTjq6rE1HFUOWdHlJ4YRYoSWZt565LOxL8lfvPFL5Fr9GVXhm9izv5H7e9YVkGgob8DHWaV77qd-UGhozhpwSmbvNF0ARoZ3PLkAdPDl-tJXbth4s36bTQz9YPIuSqXrc-iZryadrYz--F4Px6rg6mU5VZJf9INOqUyvTybUuVvtT59hraSn_j6rWVswXQurUK55nCr1zN2607P7CPVVSDjdxekrQTrKpty0qd2Wun-XOt1g99O1o9YVqNRlo9o8_s03K5AheKvS1W8oJtdjJQ-c4TA0Y6fC8y4AQGOhN68oX9LgQUcoACj0ABCquAgga0DQpPAzI4DdBogkYTEBvI0IQlmrCOJqygCTk04TuCeQoZlm3oDg1AJOWzEUlIkQREEhDJNqwP5g47vO6MLm9MHNLxXCV0Getua5dt0Eh8ZSC4h0t7l1Y8To1cBs9xpTDhE6vFm8Kpiz22W_yMPbZf3DGei8n-n-46YJua6G9sIw4X3iHau7FzJLF5B9-ytzg |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tetrahydroquinolinone+derivatives+as+potent+P-glycoprotein+inhibitors%3A+design%2C+synthesis%2C+biological+evaluation+and+molecular+docking+analysisElectronic+supplementary+information+%28ESI%29+available%3A+IR%2C+MAS+and+NMR+spectra.+See+DOI%3A+10.1039%2Fc7md00178a&rft.au=Ranjbar%2C+S&rft.au=Firuzi%2C+O&rft.au=Edraki%2C+N&rft.au=Shahraki%2C+O&rft.date=2017-10-18&rft.issn=2040-2503&rft.eissn=2040-2511&rft.volume=8&rft.issue=1&rft.spage=1919&rft.epage=1933&rft_id=info:doi/10.1039%2Fc7md00178a&rft.externalDocID=c7md00178a |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-2503&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-2503&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-2503&client=summon |